RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Guangzhou Xiangxue Life Sciences (XLifeSc), a subsidiary of Xiangxue Pharmaceutical, was approved by China’s NMPA to start clinical studies of its T-cell receptor Affinity Enhanced Specific T-cell (TAEST) therapy in patients with solid tumors. Earlier, XLifeSc announced positive results from a small pilot study of the TAEST thrapy in China. Xiangxue in-licensed the therapy from Athenex, a New York state biopharma. The two companies jointly formed Axis Therapeutics, which owns global rights (ex-China) to the TAEST therapy.
Source: China Biotoday
